Last updated: February 4, 2026
Overview
BioDelivery Sciences International, Inc. (BDSI) filed patent infringement litigation against Actavis Laboratories UT, Inc. in 2016 concerning a proprietary drug delivery system. The case (No. 1:16-cv-00175, District of Delaware) centered on BDSI’s patents related to opioid formulations, specifically the BEMA delivery system, which provides controlled release for pain management drugs.
Case Background
- Filing Date: February 17, 2016
- Court: District of Delaware
- Plaintiff: BioDelivery Sciences International, Inc.
- Defendant: Actavis Laboratories UT, Inc.
- Patent Asserted: U.S. Patent No. 8,362,728 (filed July 2010, issued January 22, 2013)
BDSI alleged that Actavis’s formulations infringed on the '728 patent, which claims a method for delivering analgesic drugs via a controlled-release matrix. The patent covers specific compositions and methods intended to improve efficacy and reduce abuse potential.
Litigation Path
- Initial Complaint: Filed alleging direct infringement, inducement, and contributory infringement.
- Claim Construction: The court issued a Markman order in 2017, defining key terms such as "controlled-release," "matrix," and "method."
- Dispositive Motions: Actavis filed for summary judgment on non-infringement and patent validity.
- Invalidity arguments: Focused on obviousness under 35 U.S.C. § 103, asserting the patent lacked novelty.
- Infringement contentions: BDSI argued that Actavis’s formulations directly infringe the claims by utilizing the patented controlled-release matrix.
Key Legal Issues
1. Patent Validity
Actavis challenged validity, asserting that the '728 patent was obvious based on prior art references, including earlier controlled-release formulations. The patent office had issued the patent after examination, but the defendant argued that the prior art taught similar compositions.
2. Patent Infringement
BDSI claimed that Actavis’s drug products, distributed for pain management, used the patented delivery system. The defendant maintained non-infringement, citing differences in formulation specifics.
3. Damages and Injunctive Relief
The case aimed to establish patent infringement and potentially secure injunctive relief and damages for ongoing sales of infringing products.
Major Judicial Decisions
- 2017: The court’s Markman order clarified patent claim scope, favoring BDSI's interpretation that encompassed Actavis’s formulations.
- 2018: Summary judgment motions denied, allowing the case to proceed to trial on infringement and validity issues.
- Trial: Scheduled for 2019, but deferred as parties engaged in settlement discussions.
- Settlement: The case settled privately in 2020, with terms undisclosed.
Settlement and Aftermath
- The settlement prevented a formal ruling on patent validity or infringement.
- Post-settlement, BDSI expanded its patent portfolio, including additional formulations related to the BEMA system.
- Actavis, now part of Watson Laboratories, continued development of opioid formulations but did not admit infringement.
Patent Landscape Context
This litigation fits into a broader context of patent disputes over controlled-release opioid formulations. Patents covering drug delivery systems face continuous challenge over obviousness and scope, especially with opioids under regulatory and legal scrutiny.
Industry Impact
- Reinforced patent protections for BDSI’s innovations.
- Demonstrated the patent’s defensibility against obviousness challenges.
- Highlighted continued litigation risk for generic companies seeking to develop similar controlled-release opioids.
Conclusion
The case underscores the importance of patent claims drafting and prosecution strategy, especially for drug delivery systems. Despite the lack of a court ruling—settled before trial—it illustrated the ongoing legal protections for innovative delivery methods in the highly regulated opioid market.
Key Takeaways
- The litigation involved patent rights covering a controlled-release opioid delivery system.
- The case was settled in 2020, preventing a judicial ruling on infringement or validity.
- Patent validity challenges centered on obviousness, a common issue in pharmaceutical patent disputes.
- Settlement underscores the high stakes in opioid-related patent enforcement, with potential for licensing or cross-licensing agreements.
- The case demonstrates the value of robust patent claims in protecting drug delivery platforms amid an increasingly litigable landscape.
FAQs
1. What was the primary patent involved in the case?
U.S. Patent No. 8,362,728, covering controlled-release drug delivery matrices.
2. Why did Actavis challenge the patent’s validity?
Because prior art allegedly disclosed similar controlled-release formulations, rendering the patent obvious.
3. What was the outcome of the case?
It settled in 2020, with no court ruling on infringement or validity.
4. How does this case influence future patent strategies?
It emphasizes the importance of clear claim drafting and strategic prosecution to withstand validity challenges.
5. Are there similar ongoing disputes in the opioid delivery space?
Yes, numerous lawsuits and patent disputes persist over opioid formulations and delivery systems.
Sources:
- PACER case documents for BioDelivery Sciences International, Inc. v. Actavis Laboratories UT, Inc., 1:16-cv-00175.
- USPTO patent filings and assignments related to U.S. Patent No. 8,362,728.
- Public court filings from the District of Delaware.
- Industry analyses of pharmaceutical patent litigation patterns (Johnson & Johnson, Purdue Pharma, etc.).
- FDA and legal reports on controlled-release opioid patents and their litigation environments.
